New pill targets tough cancers: early trial shows promise
NCT ID NCT05005234
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an oral drug called GFH925 in 334 people with advanced solid tumors that have a specific KRAS G12C mutation. The trial aimed to find the safest dose and check if the drug can shrink tumors in cancers like lung and colorectal cancer. Results will help decide if larger studies are worthwhile.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GFH925 (an oral tablet that targets a specific cancer mutation)
- What this could lead to
- If successful, this could provide a new treatment option for people with certain hard-to-treat cancers that have a KRAS G12C mutation.
- What could go wrong
- This is an early-phase trial, so the drug may not work as hoped or could cause unexpected side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for rare vascular malformations: targeted drugs enter trial
- New immunotherapy option for High-Risk pancreatic cancer patients
- New drug cocktail targets tough lung cancer mutation
- New immunotherapy targets tough pancreatic cancers in early trial
- Experimental vaccine trains immune system to fight Hard-to-Treat cancers
- New targeted pill shows promise for tough lung cancer